newsfilter
← Latest News
ClinicalTrials.gov·

A Phase 1b, Randomized, 2-Part Evaluation of Oral PF614 Relative to OxyContin - NCT05043766

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Pharmacokinetics AUC [Area Under the Curve], Pharmacokinetics Cmax [Maximum Plasma Concentration], (and 23 more...)